Immutep announces the first patient has been enrolled and safely dosed in EFTISARC-NEO, the Phase II investigator-initiated trial of eftilagimod alpha, a soluble LAG-3 protein and MHC Class II agonist, in combination with radiotherapy and the anti-PD-1 therapy KEYTRUDA for patients with soft tissue sarcoma. This chemo-free trial is the first to evaluate efti in a neoadjuvant setting. The open-label EFTISARC-NEO Phase II study, which will treat up to 40 patients, is being conducted by the Maria Skodowska-Curie National Research Institute of Oncology and is primarily funded with an approved grant from the Polish government awarded by the Polish Medical Research Agency program.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMMP:
- First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
- Immutep secures third U.S. patent for eftilagimod alpha
- Immutep completes A$80M capital raise
- Immutep granted U.S. patent for IMP761
- Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting